Ozempic Feet Linked to Rapid Fat and Muscle Loss in GLP-1 Patients

A growing number of patients using GLP-1 receptor agonists—a class of medications including Ozempic, Wegovy, Mounjaro, and Zepbound—are reporting significant changes to their feet. While not officially listed as a side effect on medication labels, the phenomenon, colloquially termed “Ozempic feet,” has become a frequent topic of conversation in podiatry clinics across the country.

Data presented at the American Diabetes Association’s 85th Scientific Sessions in 2025 indicates that the number of Americans using these therapies has increased by nearly 600 percent over the last five years. As usage rates climb, medical professionals are identifying specific, recurring foot health issues among patients undergoing rapid weight loss.

Understanding “Ozempic Feet”

Podiatric complaints related to GLP-1 use generally fall into three categories: aesthetic changes, functional pain, and shifts in shoe fit. Patients have reported that the skin on the tops of their feet appears loose, saggy, or wrinkled, with veins and tendons becoming notably more prominent.

Beyond appearance, many patients describe a “walking on pebbles” sensation, or report new instances of burning, aching, or heel pain. These changes often necessitate a change in footwear, as patients may find their previous shoes no longer fit properly, with some reporting a reduction in shoe size or a shift from a wide to a narrow foot. Experts warn that these are not merely cosmetic concerns; such changes can lead to blisters, calluses, ulcers, and, particularly in patients with diabetes, more serious wounds.

The Science of Foot Changes

The physical changes to the feet are attributed to three primary factors:

* Fat Pad Atrophy: The feet rely on natural fat pads under the heel and ball to act as shock absorbers. During rapid weight loss, these pads thin out, leaving less cushioning between the bones and the ground. This depletion is similar to the mechanism behind “Ozempic face,” where fat loss in the cheeks occurs due to the same rapid reduction of subcutaneous fat.
* Muscle Loss: GLP-1 medications can result in significant loss of lean mass, which includes muscle. According to a 2025 systematic review and meta-analysis published in the journal *Obesity*, lean mass accounted for approximately 30.8 percent of total body weight lost during therapy. Shrinking intrinsic foot muscles can alter arch support and stability, while loss of calf muscle mass may affect Achilles tendon loading and ankle stability. However, a March 2026 study by Langer and colleagues in *Cell Reports Medicine* suggests that when patients maintain resistance training, the loss of muscle mass or function may not be disproportionate.
* Structural Adaptation: Feet that have adapted to carry significant extra weight over time do not automatically “snap back” when that weight is lost. As the plantar fascia and arches adjust to a new, lower body weight, the foot structure changes, rendering old footwear ineffective.

Who Is Most at Risk?

Medical observations suggest that the most pronounced symptoms occur in patients who lose more than 15 to 20 percent of their body weight in under a year. Other risk factors include:

* Limited engagement in resistance training during the weight-loss period.
* A history of diabetes, which inherently compromises foot health.
* Advanced age, as natural fat pad atrophy occurs with aging.
* “High mileage” feet, common among individuals who are highly active or stand for long periods for work.

Context and Medical Guidance

GLP-1 medications are widely regarded as significant medical advancements, with data from the Centers for Disease Control and Prevention showing high usage rates among adults with obesity and diabetes. While these drugs can help reverse conditions like cardiovascular and liver disease, they are not without challenges.

Nausea is a common side effect, affecting an estimated 20 percent of users. Bariatric surgeons, including Dr. Betsy Dovec and Dr. Wiljon Beltre, emphasize the importance of consistent dosing. Skipping doses to mitigate nausea can disrupt the body’s adaptation to the medication, potentially worsening side effects upon restarting and causing weight loss plateaus.

Patients are advised to consult their healthcare providers regarding any new or persistent symptoms, including those affecting the feet. Before starting or continuing treatment, patients should disclose all health conditions—particularly gastroparesis, pancreatitis, or kidney issues—and provide a complete list of all medications and supplements to ensure the therapy is both safe and appropriate for their individual health history.

Find more reporting in our Health section.